Hexima’s Chief Science Officer Professor Marilyn Anderson and CEO Dr Nicole van der Weerden appeared in Saturday’s Herald Sun newspaper on 3 November. The article follows our promising results from our clinical trial for HXP124 as a treatment for fungal nail infections (onychomycosis).

View the article here.